5 Best Logistics Stocks To Buy For 2014

Shares of Tesla Motors (TSLA) are up $24.46, or 13%, at $218.10, after the company this afternoon reported Q4 revenue and earnings per shares that trounced analysts’ expectations, and said it expects to make delivery of 35,000 “Model S” sedans this year, which is higher than the Briefing.com consensus for 29,000.

Revenue in the three months ended in December rose almost 150%, year over year, to $761 million, yielding EPS of 33 cents.

Analysts had been modeling $673 million and 21 cents.

CEO Elon Musk said the company plans to increase production rate this quarter, even though actual quarterly shipments of the Model S will decline slightly from last quarter:

We expect to deliver over 35,000 Model S vehicles in 2014, representing a 55+% increase over 2013. Production is expected to increase from 600 cars/week presently to about 1,000 cars/week by end of the year as we expand our factory capacity and address supplier bottlenecks. Battery cell supply will continue to constrain our production in the first half of the year, but will improve significantly in the second half of 2014. First quarter production is expected to be about 7,400 vehicles, which is significantly higher than the prior quarter production of 6,587 cars. However, as the number of cars in transit to Europe and Asia must grow substantially to support those markets, we plan to deliver approximately 6,400 vehicles in Q1. Deliveries will grow dramatically in future quarters as the logistics pipeline fills.�This year, we expect automotive gross margin to increase to about 28% (non-GAAP and GAAP) in Q4 through a series of small design improvements, better supplier prices and economies of scale. Q1 gross margin should increase very slightly from Q4. For the remainder of the year, gross margin should improve at a faster pace.

5 Best Life Sciences Stocks To Invest In 2015: Endologix Inc(ELGX)

Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of aortic disorders. It offers the ELG System, a stent graft and delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive endovascular repair. The company also provides aortic extensions and limb extensions, which attach to the main body of ELG Device, enabling physicians to customize it to fit the patient?s anatomy. In addition, it offers accessories, such as guidewires, snares, and catheter introducer sheaths that facilitate the optimal delivery of its ELG Device. Endologix, Inc. sells its products through direct sales force and independent distributors in the United States, Europe, Asia, South America, and Mexico. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Endologix (NASDAQ: ELGX) were down 24.85 percent to $13.43 on lowered guidance, analyst downgrades. Oppenheimer downgraded the stock from Outperform to Market Perform and cut the price target from $20.00 to $16.00.

• [By Jake L'Ecuyer]

  Equities Trading DOWN
  Shares of Endologix (NASDAQ: ELGX) were down 23.48 percent to $13.68 on lowered guidance, analyst downgrades. Oppenheimer downgraded the stock from Outperform to Market Perform and cut the price target from $20.00 to $16.00.

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Endologix (Nasdaq: ELGX  ) , whose recent revenue and earnings are plotted below.

5 Best Logistics Stocks To Buy For 2014: Epizyme Inc (EPZM)

Epizyme, Inc., incorporated on November 1, 2007, is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. The Company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer.The Company is conducting a Phase I clinical trial of its advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia (MLL-r). The Company has identified its two lead product candidates using its product platform.

EPZ-5676-DOT1L Inhibitor

EPZ-5676 is an intravenously administered small molecule inhibitor of DOT1L. The Company is developing EPZ-5676 for the treatment of MLL-r, an aggressive subtype of the two most common forms of acute leukemia, ALL and AML. Patients with MLL-r are routinely diagnosed with existing technologies that are commonly used in clinical setting. The Company�� Phase 1 clinical trial of EPZ-5676 is an open label, multicenter trial that has two phases.

EPZ-6438-EZH2 Inhibitor

The Company is developing EPZ-6438 as an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients who have an oncogenic point mutation in EZH2. EZH2 is an HMT that can become oncogenic and cause non-Hodgkin lymphoma and a range of other solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are particularly associated with an EZH2 point mutation. There are no therapies approved specifically for the treatment of cancer associated with an EZH2 point mutation.

Advisors' Opinion:

• [By John Udovich]

  It�� a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or�pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for�Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ:�RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:

• [By John Udovich]

  On Tuesday, small cap biopharmaceutical company Epizyme Inc (NASDAQ: EPZM) surged 75.56% after the company announced that its�EPZ-5676, a DOT1L inhibitor for acute leukemias, had reached its proof-of-concept milestone, meaning its worth taking a closer look at the stock as well as look at the share performance of cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Dendreon Corporation (NASDAQ: DNDN) and Geron Corporation (NASDAQ: GERN).

• [By Lisa Levin]

  Epizyme (NASDAQ: EPZM) shares rose 66.84% to $34.20. The volume of Epizyme shares traded was 1683% higher than normal. Epizyme reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.

5 Best Logistics Stocks To Buy For 2014: LPL Investment Holdings Inc.(LPLA)

LPL Investment Holdings Inc. provides an integrated platform of brokerage and investment advisory services to independent financial advisors and financial advisors at financial institutions in the United States. The company?s brokerage offerings include variable and fixed annuities, mutual funds, general securities, alternative investments, retirement and 529 education savings plans, and fixed income; and insurance offerings comprise personalized advance case design, point-of-sale service, and product support for a range of life, disability, and long-term care products. Its fee-based advisory platforms and support solutions offer access to no-load/load-waived mutual funds, exchange-traded funds, stocks, bonds, conservative option strategies, unit investment trusts and no-load, institutional money managers, and multi-manager variable annuities through five platforms, as well as third-party equity research and asset-management services, and fee-based advisory and consulting services to retirement plans. The company?s cash sweep programs consist of money market sweep vehicles and an insured bank deposit sweep vehicles. Its services also include tools and services that enable advisors to maintain their practice; and trust, investment management oversight, and custodial services for estates and families, as well as technology and open architecture investment management solutions to trust departments of financial institutions. LPL Investment Holdings Inc. provides its services to approximately 12,800 independent financial advisors from a range of firms, including wirehouses, regional and insurance broker dealers, banks, and other independent firms; and registered investment advisors, and advisors at small and mid-sized financial institutions. The company was founded in 1968 and is headquartered in Boston, Massachusetts.

Advisors' Opinion:

• [By Marc Bastow]

  Global investment and financial advisory services holding company LPL Financial Holdings (LPLA) raised its quarterly dividend 26.3% to 24 cents per share, payable March 10 to shareholders of record as of Feb. 24.
  LPLA Dividend Yield: 1.81%

• [By Ben Levisohn]

  Discount brokers had a great 2013, in large part because of the perceived boost they would get from rising interest rates and rising stock prices. Charles Schwab returned 83%, E*Trade Financial (ETFC) surged 119%, TD Ameritrade (AMTD) rose 88%, and LPL Financial (LPLA) finished the year up 69%.

5 Best Logistics Stocks To Buy For 2014: Tenneco Automotive Inc.(TEN)

Tenneco Inc. designs, manufactures, and sells emission control and ride control products and systems for light, commercial, and specialty vehicle applications worldwide. The company offers emission control systems, such as catalytic converters and diesel oxidation catalysts to reduce harmful gaseous emissions; diesel particulate filters to eliminate particulate matter emitted from diesel engines; burner systems, which combust fuel and air inside the exhaust system; and hydrocarbon vaporizers and injectors. It also provides lean nitrogen oxide traps, selective catalytic reduction systems, and alternative NOx reduction technologies that reduce nitrogen oxide emissions from diesel power trains; mufflers and resonators to provide noise elimination and acoustic tuning; exhaust manifolds that collect gases from individual cylinders of a vehicle?s engine and direct them into a single exhaust pipe; pipes to connect various parts of hot and cold ends of an exhaust system; hydro fo rmed assemblies; hangers and isolators used for system installation and elimination of noise and vibration; and after treatment control units. In addition, the company offers ride control systems comprising shock absorbers, struts, vibration control components, a suite of roll-control and nearly equal wheel-loading systems, and advanced suspension systems, as well as other ride control products, including load assist products, springs, steering stabilizers, suspension kits, and modular assemblies. The company provides its products under the Monroe, Rancho, Clevite Elastomers, Marzocchi, Axios, Kinetic, Fric-Rot, Walker, Fonos, DynoMax, Thrush, and Lukey brands. It serves original equipment manufacturers, and repair and replacement markets. The company was formerly known as Tenneco Automotive Inc. and changed its name to Tenneco Inc. in 2005. Tenneco Inc. was founded in 1987 and is headquartered in Lake Forest, Illinois.

Advisors' Opinion:

• [By Stephen Quickel]

  Tenneco Inc. (TEN)

  Located cross town from PKG in Lake Forest, TEN is a supplier emissions control and other auto parts with revenues of $9 billion. Earnings growth is estimated at 19% a year with an 11.4 P/E and a 0.60 PEG.

• [By Ben Levisohn]

  Shares of Lear have gained 0.2% to $77.32 at 2:24 p.m. on a day when most auto-part companies are not doing much of anything.�Delphi Automotive, the big loser, has dropped 1.1% to $57.39,�Johnson Controls�(JCI) has fallen 0.2% to $42.94 and�Borg Warner�(BWA) has risen up 0.4% to $106.70. The big winner: Tenneco�(TEN), which has jumped 3.3% $54.65 after reporting better than expected earnings.